Cetuximab in combination with oxaliplatin/5-fluorouracil (5FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer:: An international phase II study.

被引：0
|
作者：
Rubio, ED
Tabernero, J
van Cutsem, E
Cervantes, A
André, T
Humblet, Y
Soulié, P
Corretgé, S
Kisker, O
de Gramont, A
机构：
[1] Hosp Clin San Carlos, Madrid, Spain
[2] Hosp Univ Vall Hebron, Barcelona, Spain
[3] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[4] Hosp Clin Univ, Valencia, Spain
[5] Hop Tenon, F-75970 Paris, France
[6] Clin Univ St Luc, Brussels, Belgium
[7] Ctr Paul Papin, Angers, France
[8] Merck Farma & Quim, Barcelona, Spain
[9] Merck KGaA, Darmstadt, Germany
[10] Hop St Antoine, F-75571 Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：254S / 254S
页数：1
相关论文
共 50 条
  • [31] An oxaliplatin plus 5-fluorouracil bolus plus folinic acid (BFOL) regimen as first-line treatment in metastatic colorectal cancer patients
    La Verde, Nicla
    Garassino, Marina
    Bareggi, Claudia
    Sburlati, Paola
    Borgonovo, Karen
    Dimaiuta, Mariastella
    Mantica, Cristina
    Perrone, Silvia
    Torri, Valter
    Farina, Gabriella
    TUMORI, 2007, 93 (06) : 557 - 561
  • [32] Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer
    Tabernero, Josep
    Van Cutsem, Eric
    Diaz-Rubio, Eduardo
    Cervantes, Andres
    Humblet, Yves
    Andre, Thierry
    Van Laethem, Jean-Luc
    Soulie, Patrick
    Casado, Esther
    Verslype, Chris
    Valera, Javier Sastre
    Tortora, Giampaolo
    Ciardiello, Fortunato
    Kisker, Oliver
    de Gramont, Aimery
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5225 - 5232
  • [33] Phase II study of oxaliplatin (OHP) and protracted 5-fluorouracil (5FU) infusion in pretreated metastatic colorectal cancer (MCRC) patients
    Mini, E
    Pinto, C
    Angelelli, B
    Dentico, P
    Piana, E
    Nobili, S
    Gentile, AL
    Scicolone, S
    Mazzei, T
    Martoni, A
    ANNALS OF ONCOLOGY, 2000, 11 : 73 - 73
  • [34] Efficacy and Safety of Oxaliplatin, 5-Fluorouracil, and Folinic Acid Combination Chemotherapy as First-Line Treatment in Metastatic or Recurrent Gastric Cancer
    Kim, Han Jo
    Eun, Jun Young
    Jeon, Young Woo
    Yun, Jina
    Kim, Kyoung Ha
    Kim, Se Hyung
    Kim, Hyun Jung
    Lee, Sang-Cheol
    Bae, Sang Byung
    Kim, Chan Kyu
    Lee, Nam Su
    Lee, Kyu Taek
    Park, Seong-Kyu
    Won, Jong-Ho
    Hong, Dae Sik
    Park, Hee Sook
    CANCER RESEARCH AND TREATMENT, 2011, 43 (03): : 154 - 159
  • [35] Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
    Gunnar Folprecht
    Susanne Hamann
    Katharina Schütte
    Tanja Trarbach
    Jan Stoehlmacher-Williams
    Gerhard Ehninger
    BMC Cancer, 14
  • [36] Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
    Folprecht, Gunnar
    Hamann, Susanne
    Schuete, Katharina
    Trarbach, Tanja
    Stoehlmacher-Williams, Jan
    Ehninger, Gerhard
    BMC CANCER, 2014, 14
  • [37] Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study
    Rothenberg, M. L.
    Cox, J. V.
    Butts, C.
    Navarro, M.
    Bang, Y. -J.
    Goel, R.
    Gollins, S.
    Siu, L. L.
    Laguerre, S.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2008, 19 (10) : 1720 - 1726
  • [38] Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study
    Folprecht, G.
    Pericay, C.
    Saunders, M. P.
    Thomas, A.
    Lopez Lopez, R.
    Roh, J. K.
    Chistyakov, V.
    Hoehler, T.
    Kim, J. -S.
    Hofheinz, R. -D.
    Ackland, S. P.
    Swinson, D.
    Kopp, M.
    Udovitsa, D.
    Hall, M.
    Iveson, T.
    Vogel, A.
    Zalcberg, J. R.
    ANNALS OF ONCOLOGY, 2016, 27 (07) : 1273 - 1279
  • [39] Cost-effectiveness of oxaliplatin/5FU/LV (FOLFOX) vs. irinotecan/5FU/LV (IFL) as first-line treatment of metastatic colorectal cancer
    Aballea, S.
    Najib, M.
    Cure, S.
    O'Neil, B.
    ANNALS OF ONCOLOGY, 2006, 17 : 66 - 66
  • [40] Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study
    Christos Emmanouilides
    Georgia Sfakiotaki
    Nikolaos Androulakis
    Kostas Kalbakis
    Charalambos Christophylakis
    Antonia Kalykaki
    Lambros Vamvakas
    Athanasios Kotsakis
    Sofia Agelaki
    Eleni Diamandidou
    Nikolaos Touroutoglou
    Adam Chatzidakis
    Vassilis Georgoulias
    Dimitris Mavroudis
    John Souglakos
    BMC Cancer, 7
12345